2 results
Approved WMOCompleted
Objectives:Primary* Phase Ib: to determine the maximum tolerated dose (MTD) recommended for Phase II of eribulin mesylate (eribulin), administered in combination with gemcitabine plus cisplatin in patients with locally advanced or metastatic bladder…
Approved WMOCompleted
To assess the efficacy of GV-971 compared with placebo on cognition and global function in participants with mild to moderate Alzheimer's disease (AD).